Lukas Scheibler Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Lukas Scheibler is Chief Research Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 68,299 shares of APLS, which is worth approximately $2.23 Million. The most recent transaction as insider was on Dec 01, 2023, when has been sold 10,000 shares (Common Stock) at a price of $60.0 per share, resulting in proceeds of $600,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 68.3K

0% 3M change

0% 12M change

Total Value Held $2.23 Million

LUKAS SCHEIBLER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2023	SELL Open market or private sale	$600,000 $60.0 p/Share	10,000 Reduced 12.77%	68,299 Common Stock
Dec 01 2023	BUY Exercise of conversion of derivative security	$138,500 $13.85 p/Share	10,000 Added 11.33%	78,299 Common Stock
Sep 06 2023	SELL Open market or private sale	$75,525 $43.01 p/Share	1,756 Reduced 2.51%	68,299 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$41,827 $58.5 p/Share	715 Reduced 1.02%	69,643 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	9,886 Added 12.32%	70,358 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$34,720 $51.21 p/Share	678 Reduced 1.11%	60,472 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$28,601 $52.77 p/Share	542 Reduced 0.88%	61,150 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$104,880 $52.05 p/Share	2,015 Reduced 3.16%	61,692 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	22,580 Added 26.17%	63,707 Common Stock
May 27 2022	SELL Open market or private sale	$430,000 $43.0 p/Share	10,000 Reduced 19.86%	40,358 Common Stock
Apr 21 2022	SELL Other acquisition or disposition	-	1,875 Reduced 3.59%	50,358 Common Stock
Apr 05 2022	SELL Open market or private sale	$36,595 $60.09 p/Share	609 Reduced 1.15%	52,233 Common Stock
Apr 05 2022	BUY Exercise of conversion of derivative security	$8,435 $13.85 p/Share	609 Added 1.14%	52,842 Common Stock
Apr 04 2022	SELL Open market or private sale	$199,132 $56.83 p/Share	3,504 Reduced 6.29%	52,233 Common Stock
Apr 04 2022	BUY Exercise of conversion of derivative security	$48,530 $13.85 p/Share	3,504 Added 5.91%	55,737 Common Stock
Apr 01 2022	SELL Open market or private sale	$632,855 $55.05 p/Share	11,496 Reduced 18.04%	52,233 Common Stock
Apr 01 2022	BUY Exercise of conversion of derivative security	$159,220 $13.85 p/Share	11,496 Added 15.28%	63,729 Common Stock
Feb 14 2022	BUY Exercise of conversion of derivative security	$19,246 $26.73 p/Share	720 Added 1.36%	52,233 Common Stock
Feb 11 2022	SELL Open market or private sale	$77,969 $46.8 p/Share	1,666 Reduced 3.13%	51,513 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$31,947 $47.12 p/Share	678 Reduced 1.26%	53,179 Common Stock
Feb 10 2022	SELL Open market or private sale	$500,000 $50.0 p/Share	10,000 Reduced 15.83%	53,179 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	$138,500 $13.85 p/Share	10,000 Added 13.67%	63,179 Common Stock
Feb 08 2022	SELL Open market or private sale	$450,000 $45.0 p/Share	10,000 Reduced 15.66%	53,857 Common Stock
Feb 08 2022	BUY Exercise of conversion of derivative security	$138,500 $13.85 p/Share	10,000 Added 13.54%	63,857 Common Stock
Jan 31 2022	SELL Open market or private sale	$47,434 $38.47 p/Share	1,233 Reduced 2.24%	53,857 Common Stock

Lukas Scheibler

Chief Research Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account